Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy on March 5, 2026, strengthening clinical leadership for its cardiorenal and pediatric focus.
Dr. Goldstein, a noted pediatric nephrology and critical care expert, will advise on product development, evidence generation, pediatric innovation, and educational initiatives to advance precision fluid management and AKI care.
Positive
- Seniority: Appointment of a leading pediatric nephrology expert strengthens clinical credibility
- Strategy: Direct support for pediatric innovation, evidence generation, and precision fluid management
- Clinical roadmap: Expected to guide product development and educational initiatives for cardiorenal care
Negative
- None.
News Market Reaction – NUWE
In the Mar 5 session, NUWE declined 5.13%, reflecting a notable negative market reaction. Argus tracked a trough of -15.6% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Board appointments | Positive | -3.6% | Added experienced directors to support strategic execution and capital markets access. |
| Feb 24 | Earnings date set | Neutral | -4.7% | Scheduled Q4 and full-year 2025 results call and business update. |
| Jan 30 | CFO appointment | Positive | -10.0% | Named a new CFO with medical-technology and public company finance experience. |
| Jan 29 | Private placement | Negative | -10.0% | Announced a $5.0M priced-at-the-market private placement and warrant inducement. |
| Jan 29 | Acquisition deal | Positive | -10.0% | Agreed to acquire Rendiatech to expand real-time kidney function monitoring portfolio. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows NUWE often trading lower on strategic and leadership news, with private placement dilution aligning with a negative move.
Over the last few months, Nuwellis has executed several strategic steps. On Jan 29, 2026, it announced a $5.0 million private placement and a definitive agreement to acquire Rendiatech, both followed by a -10.02% move. Subsequent leadership changes, including appointing a new CFO on Jan 30, 2026 and two new board members on Feb 24, 2026, also saw negative price reactions. Today’s appointment of a Director of Clinical Strategy fits this ongoing cardiorenal-focused buildout of management and capabilities.
Key Terms
acute kidney injury medical
continuous renal replacement therapies medical
fluid overload medical
hemodynamic stability medical
ultrafiltration medical
cardiorenal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney Injury
MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy.
Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understanding of acute kidney injury (AKI), fluid overload, and the use of continuous renal replacement therapies in critically ill children.
Dr. Goldstein’s research has been foundational in demonstrating the relationship between fluid overload and mortality in critically ill pediatric patients, including landmark studies through the Prospective Pediatric Continuous Renal Replacement Therapy Registry. His work has significantly shaped global standards for early identification and management of AKI and fluid balance in critically ill populations.
As Director of Clinical Strategy , Dr. Goldstein will consult with and advise Nuwellis on clinical feedback, product development, pediatric innovation, evidence generation, and educational initiatives aligned with the company’s evolving cardiorenal focus. His expertise will directly support Nuwellis’ commitment to advancing precision fluid management solutions that address the critical interplay between the heart and kidneys across the continuum of care.
“Our cardiorenal strategy is rooted in the science of fluid balance and the clinical consequences of fluid overload,” said Kelsey Newell, Sr. Director of Medical Affairs at Nuwellis. “Dr. Goldstein’s pioneering work in pediatric AKI and fluid management has shaped how the medical community understands the impact of fluid overload on outcomes. His insight will strengthen our clinical evidence roadmap, guide responsible innovation, and ensure our technologies are aligned with the needs of critically ill children and adults.”
Dr. Goldstein added, “Fluid overload remains one of the most important modifiable risk factors in critically ill patients, yet it is often addressed too late or with limited precision. Nuwellis is focused on advancing technologies that allow clinicians to intervene earlier and manage volume status more thoughtfully. I look forward to working with the team to help generate evidence, educate clinicians, and support a more proactive cardiorenal approach to care.”
Nuwellis’ cardiorenal strategy centers on early identification of fluid overload, precision ultrafiltration, and technologies designed to safely remove excess fluid while preserving hemodynamic stability. The company continues to expand its clinical and scientific partnerships to drive better outcomes for patients with heart failure, acute kidney injury, and complex cardiorenal conditions.
For more information, visit www.nuwellis.com.
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company advancing precision fluid management technologies across the cardiorenal continuum. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations.
About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
